StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson REMICADE (infliximab) — Worldwide sales by Quarter

REMICADE (infliximab) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson REMICADE (infliximab) — Worldwide sales: $394M in Q3 2026, down 17.2% from a year earlier.

Latest, Q3 2026
394
Period ended Sep 30, 2026
Change on a year earlier
-17.2%
476 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-21) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedREMICADE (infliximab) — Worldwide sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026394-17.2%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 2026338-25.7%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 2026422-9.6%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 2025370+3.1%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 2025476+13.6%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 2025455+15.8%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 2025467+7.6%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 2024359-16.3%Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 2024419-9.1%Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 2024393-14.9%Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 2024434-10.9%Form 10-Q (filed 2025-04-23) ↗
Q4 2023Dec 31, 2023429-9.7%Form 10-K (filed 2026-02-11) ↗
Q3 2023Oct 1, 2023461-17.4%Form 10-Q (filed 2024-10-23) ↗
Q2 2023Jul 2, 2023462-28.6%Form 10-Q (filed 2024-07-25) ↗
Q1 2023Apr 2, 2023487-26.5%Form 10-Q (filed 2024-05-01) ↗
Q4 2022Jan 1, 2023475-37.8%Form 10-K (filed 2025-02-13) ↗

Breakdown

What makes up REMICADE (infliximab) — Worldwide sales

Cite this data

StockData. (2026). Johnson & Johnson REMICADE (infliximab) — Worldwide sales ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-remicade

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.